Phosphodiesterase 5 inhibitors in vascular systemic disorders

被引：4
作者：
Allanore, Yannick [1 ]
机构：
[1] Univ Paris 05, INSERM U1016, Serv Rhumatol, Hop Cochin, F-75014 Paris, France
来源：
JOINT BONE SPINE | 2012年 / 79卷 / 04期
关键词：
Phosphodiesterase; Nitric oxide; Pulmonary hypertension; Raynaud's phenomenon; Sildenafil; Tadalafil; PULMONARY ARTERIAL-HYPERTENSION; RAYNAUDS-PHENOMENON RESISTANT; DOUBLE-BLIND; SILDENAFIL; THERAPY; TADALAFIL; SCLEROSIS; EFFICACY;
D O I：
10.1016/j.jbspin.2011.12.009
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：338 / 340
页数：3
相关论文
共 50 条
  • [21] Cardiovascular effects of phosphodiesterase 5 inhibitors
    Reffelmann, Thorsten
    Kloner, Robert A.
    CURRENT PHARMACEUTICAL DESIGN, 2006, 12 (27) : 3485 - 3494
  • [22] Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review
    Shafiee, Arman
    Bahri, Razman Arabzadeh
    Teymouri Athar, Mohammad Mobin
    Afsharrezaei, Fatemeh
    Gholami, Mostafa
    BMC GASTROENTEROLOGY, 2023, 23 (01)
  • [23] Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey
    Kim, NN
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2003, 15 (Suppl 5) : S13 - S19
  • [24] Oral phosphodiesterase type 5 inhibitors and priapism: A VigiBase analysis
    Abbasi, Behzad
    Shaw, Nathan M.
    Lui, Jason L.
    Hakam, Nizar
    Nabavizadeh, Behnam
    Breyer, Benjamin N.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 (01)
  • [25] Phosphodiesterase-5 inhibitors and rosacea: report of 10 cases
    Ioannides, D.
    Lazaridou, E.
    Apalla, Z.
    Devliotou-Panagiotidou, D.
    BRITISH JOURNAL OF DERMATOLOGY, 2009, 160 (03) : 719 - 720
  • [26] Effects of phosphodiesterase type 5 inhibitors on Raynaud’s phenomenon
    Yasuyuki Kamata
    Seiji Minota
    Rheumatology International, 2014, 34 : 1623 - 1626
  • [27] Therapeutic Potentials of Phosphodiesterase-5 Inhibitors in Cardiovascular Disease
    Ha Nguyen
    Amanullah, Aman M.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2014, 15 (02) : 158 - 167
  • [28] Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey
    N N Kim
    International Journal of Impotence Research, 2003, 15 : S13 - S19
  • [29] Phosphodiesterase type 5 inhibitors in the treatment of pulmonary arterial hypertension
    Kilickesmez, Kadriye
    Kucukoglu, M. Serdar
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2010, 10 : 16 - 18
  • [30] From Celecoxib to a Novel Class of Phosphodiesterase 5 Inhibitors: Trisubstituted Pyrazolines as Novel Phosphodiesterase 5 Inhibitors with Extremely High Potency and Phosphodiesterase Isozyme Selectivity
    Abdel-Halim, Mohammad
    Sigler, Sara
    Racheed, Nora A. S.
    Hefnawy, Amr
    Fathalla, Reem K.
    Hammam, Mennatallah A.
    Maher, Ahmed
    Maxuitenko, Yulia
    Keeton, Adam B.
    Hartmann, Rolf W.
    Engel, Matthias
    Piazza, Gary A.
    Abadi, Ashraf H.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (08) : 4462 - 4477
12345